The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of efficacy.
Authors
Hillmen, PRawstron, A
Munir, T
Brock, K
Vincente, S
Jefferson, Y
Paterson, K
Fox, C
Gribben, J
Bloor, Adrian
Schuh, A
Forconi, F
Affiliation
Univ Leeds, Expt Haematol, LeedsIssue Date
2017